 The FDA has signed off the expansion of Phase 1 testing of a COVID-19 vaccine candidate, developed by NantKwest Incs NASDAQ: NK merger partner, ImmunityBio Inc, to include sublingual boosts cohort C expansion to the currently active multi-cohort trial of the subcutaneous version of the vaccine. The agency also authorized a second Phase 1 study that will examine the addition of an oral boost to the subcutaneous prime administration. 